Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (525)	8/22/2002 12:24:22 PM
From: Jibacoa	Read Replies (1) \| Respond to of 544

XOMA Is now closing some of its April 5 down-gap.<g> It started on an UP-TREND on August 6. (The P,S,M,L data at that time was:4.39; 4.23; 4.05 & 4.04) The present data: 6.15; 5.79; 5.14 & 4.50 siliconinvestor.com siliconinvestor.com Bernard

To: Jibacoa who wrote (525)	8/24/2002 1:12:41 PM
From: Jibacoa	Respond to of 544

SQNM Still is not on an UP-TREND.<g> (The price and the S & M averages are O.K. but the L average isn't as yet.<g>) The present data:2.60; 2.36; 2.24 & 2.82 ( I would expect for it to hold the 2.25 and continue the up-move on a close above 2.85) In spite of the 56.7% gain from the Ls this week (on August 20) it is still selling at 0.6 of book and below its reported cash/share of $2.94. The loss on June 30 was trimmed to $0.04 compared with the $0.39 on the second Q. The acquisition of Axiom Biotechnologies is expected to result in less than 5% dilution and to accelerate its internal biology, assay and drug discovery capabilities, by up to two years. They continue to sell their MassARRAY systems at an accelerated pace. They expect to launch a medium-throughput, medium-cost MassARRAY system in 2003, which should broaden the market reach to the larger market segment that does not require high-throughput capabilities. Their pharmaceutical unit has identified more than 400 high-impact candidate genes , of which at least 40 are high-confidence "multiple hits." They have concentrated their efforts on cancer, cardiovascular and metabolic diseases and a study focusing on breast cancer, is already underway. The analyst consensus for SQNM has a "target price" of $10, but I would be satisfied with $8.<g> Bernard